NS

Nainmal Surana

Director Director DIN 02150686
DIN 02150686 First appointment Oct 1996 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 1996
Shareholding value •••• Premium profile

About Nainmal Surana

Data last updated:

Nainmal Surana was a Director at Raja Antibiotics Limited (1996–2010) and Director at Angeas Health Care Limited (2003–2010). The companies operate in Pharma.

DIN 02150686
Primary Designation Director
Industry Pharma
First Appointment 01 Oct 1996

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Raja Antibiotics Limited U24233MH1995PLC091177
Director01 Oct 19961995₹4.46 Cr (FY 2019)Active
Angeas Health Care Limited U85113MH2003PLC141378
Director17 Jul 20032003₹35.3 Lakh (FY 2016)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Raja Antibiotics Limited
Angeas Health Care Limited
Premium access

Shareholding and investment profile for Nainmal Surana

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nainmal Surana

Nainmal Surana was first appointed on 01 Oct 1996 as Director at Raja Antibiotics Limited. The most recent appointment on record is 17 Jul 2003 at Angeas Health Care Limited.

Nainmal Surana held 2 earlier board appointments: Raja Antibiotics Limited (Director, 01 Oct 1996 to 05 Mar 2010); Angeas Health Care Limited (Director, 17 Jul 2003 to 05 Mar 2010).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available